Siegfried Holding AG, commonly referred to as Siegfried, is a prominent player in the pharmaceutical and chemical industry, headquartered in Switzerland (CH). Founded in 1873, the company has established a strong presence in Europe and North America, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. Siegfried is renowned for its innovative solutions in contract development and manufacturing, catering to a diverse clientele in the pharmaceutical sector. The company’s commitment to quality and sustainability sets it apart, ensuring compliance with stringent regulatory standards. With a robust market position, Siegfried has achieved significant milestones, including strategic acquisitions that have expanded its capabilities and global reach. As a trusted partner in the pharmaceutical supply chain, Siegfried continues to drive advancements in drug development and production.
How does Siegfried Holding's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Siegfried Holding's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Siegfried Holding AG reported total carbon emissions of approximately 59171000 kg CO2e for Scope 1, 12622000 kg CO2e for Scope 2, and 459700000 kg CO2e for Scope 3, resulting in a combined total of about 71793000 kg CO2e for Scope 1 and 2 emissions. This reflects a slight increase in Scope 1 emissions compared to 2023, where they were approximately 58411000 kg CO2e, and a decrease in Scope 2 emissions from 14617000 kg CO2e. Siegfried has set ambitious climate commitments, aiming for a 50% reduction in its Scope 1 and 2 emissions by 2030, based on 2020 revenue-adjusted figures. Additionally, the company has committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050. Near-term targets include a 66.89% reduction in absolute Scope 1 and 2 emissions by 2033 from a 2020 baseline, and a 32.5% reduction in Scope 3 emissions from specific categories by 2033, using 2022 as the baseline year. These targets are aligned with the Science Based Targets initiative (SBTi) and demonstrate Siegfried's commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector. The company is also focused on ensuring that 85% of its suppliers have science-based targets by 2029, further enhancing its sustainability efforts.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,300,000 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Siegfried Holding has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Siegfried Holding's sustainability data and climate commitments